A Study to evaluate effect of AZD6234 in adult participants with obesity or overweight with weight-related comorbidity without Type 2 Diabetes Mellitus - SELENE 1

Study identifier:D8750C00014

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:2025-523379-41

Recruiting

Official Title

A Phase III Randomised, Double-Blind, Placebo-Controlled Multicentre Trial to Evaluate the Efficacy and Safety of AZD6234 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity Without Type 2 Diabetes Mellitus (SELENE 1)

Medical condition

Obesity or Overweight

Phase

Phase 3

Healthy volunteers

No

Study drug

AZD6234, Placebo

Sex

All

Estimated Enrollment

2500

Study type

Interventional

Age

18 Years - n/a

Date

Study Start Date: 19 Aug 2026
Estimated Primary Completion Date: 11 Aug 2028
Estimated Study Completion Date: 21 May 2029

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2026 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria